DUPIXENT® (dupilumab) is a prescription medicine used to treat people aged 6 years and older with moderate-to-severe atopic dermatitis (eczema) that is not well controlled with prescription therapies used on the skin (topical), or who cannot use topical therapies.

Learn about DUPIXENT® (dupilumab) for moderate-to-severe asthma treatment. DUPIXENT® is a prescription medicine used as an add-on maintenance treatment for uncontrolled moderate-to-severe eosinophilic or oral steroid dependent asthma in people aged 6 years and older.

Learn more about DUPIXENT® (dupilumab), the first FDA-approved biologic treatment for adults with inadequately controlled COPD (chronic obstructive pulmonary disease) and a high number of blood eosinophils.

DUPIXENT® (dupilumab) is a subcutaneous injectable prescription medicine for uncontrolled moderate-to-severe eczema (atopic dermatitis) in adults & children aged 6 months & older. Serious side effects can occur.

Find answers to frequently asked questions about DUPIXENT® (dupilumab), a prescription medicine FDA-approved to treat six conditions. Including how to administer DUPIXENT®, common side effects, and results seen in DUPIXENT® clinical trials.

DUPIXENT® (dupilumab)為皮下注射的處方藥物，用於治療患有難以控制的中度至重度濕疹(異位性皮膚炎)的成人和6個月以上兒童。可能會引起嚴重的副作用。請參閱網站上的重要安全資訊及患者資訊。

Find information on insurance coverage, ordering through a specialty pharmacy, and the cost of DUPIXENT® (dupilumab), a prescription medicine FDA-approved to treat six conditions. Serious side effects can occur.

Learn how DUPIXENT® (dupilumab) works to treat a source of underlying inflammation that can contribute to uncontrolled, moderate-to-severe eczema in adults and children aged 6 months & older. Serious side effects can occur.

Learn more about DUPIXENT® (dupilumab), the first FDA-approved biologic to treat eosinophilic esophagitis (EoE) in adult and pediatric patients aged 1 year and older who weigh at least 33lb (15kg). Serious side effects can occur.

Learn about injection options for inadequately controlled COPD (chronic obstructive pulmonary disease) and a high number of blood eosinophils by DUPIXENT® (dupilumab), the 300mg pre-filled syringe and 300mg pre-filled pen.